These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37104792)

  • 1. Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.
    Pinto FFE; Mello CAL; Nakagawa SA; Chung WT; Torrezan GT; Barros BDF; Cunha IW; Calsavara VF; Carraro DM; Lopes A
    Clin Orthop Relat Res; 2023 Oct; 481(10):1978-1989. PubMed ID: 37104792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
    Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
    Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data.
    Timbergen MJM; Colombo C; Renckens M; Kim HS; Rosmalen JV; Salas S; Mullen JT; Colombo P; Nishida Y; Wiemer EAC; Verhoef C; Sleijfer S; Gronchi A; Grünhagen DJ
    Ann Surg; 2021 Jun; 273(6):1094-1101. PubMed ID: 31804402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan.
    Nishida Y; Hamada S; Kawai A; Kunisada T; Ogose A; Matsumoto Y; Ae K; Toguchida J; Ozaki T; Hirakawa A; Motoi T; Sakai T; Kobayashi E; Gokita T; Okamoto T; Matsunobu T; Shimizu K; Koike H
    Cancer Sci; 2020 Aug; 111(8):2935-2942. PubMed ID: 32539220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
    Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
    van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T
    Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
    Lazar AJ; Tuvin D; Hajibashi S; Habeeb S; Bolshakov S; Mayordomo-Aranda E; Warneke CL; Lopez-Terrada D; Pollock RE; Lev D
    Am J Pathol; 2008 Nov; 173(5):1518-27. PubMed ID: 18832571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis.
    Penel N; Bonvalot S; Bimbai AM; Meurgey A; Le Loarer F; Salas S; Piperno-Neumann S; Chevreau C; Boudou-Rouquette P; Dubray-Longeras P; Kurtz JE; Guillemet C; Bompas E; Italiano A; Le Cesne A; Orbach D; Thery J; Le Deley MC; Blay JY; Mir O
    Clin Cancer Res; 2022 Sep; 28(18):4105-4111. PubMed ID: 35294527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of
    Guo L; Wang X; Xu B; Lang R; Hu B
    Future Oncol; 2021 Feb; 17(4):435-442. PubMed ID: 33397129
    [No Abstract]   [Full Text] [Related]  

  • 10. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
    Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
    PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CORR Insights®: Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.
    Ramsey DC
    Clin Orthop Relat Res; 2023 Oct; 481(10):1990-1992. PubMed ID: 37159234
    [No Abstract]   [Full Text] [Related]  

  • 12. PROMIS Function Scores Are Lower in Patients Who Underwent More Aggressive Local Treatment for Desmoid Tumors.
    Newman ET; Lans J; Kim J; Ferrone M; Ready J; Schwab J; Raskin K; Calderon SL
    Clin Orthop Relat Res; 2020 Mar; 478(3):563-577. PubMed ID: 31429829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis.
    Crago AM; Denton B; Salas S; Dufresne A; Mezhir JJ; Hameed M; Gonen M; Singer S; Brennan MF
    Ann Surg; 2013 Aug; 258(2):347-53. PubMed ID: 23532110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological and molecular genetic features of neuromuscular choristoma-associated desmoid type fibromatosis].
    Dong RF; Guo W; Li N; Wang ZY; Sun XQ; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):685-690. PubMed ID: 38955699
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor.
    Carrillo-García J; Hindi N; Conceicao M; Sala MÁ; Ugalde A; López-Pousa A; Bagué S; Sevilla I; Vicioso L; Ramos R; Martínez-Trufero J; Gómez Mateo MC; Cruz J; Hernández-León CN; Redondo A; Mendiola M; García JM; Hernández JE; Álvarez R; Agra C; de Juan-Ferré A; Valverde C; Cano JM; Sande LM; Pérez-Fidalgo JA; Lavernia J; Marcilla D; Gutiérrez A; Moura DS; Martín-Broto J
    Eur J Cancer; 2024 Sep; 209():114270. PubMed ID: 39142211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis.
    Colombo C; Fiore M; Grignani G; Tolomeo F; Merlini A; Palassini E; Collini P; Stacchiotti S; Casali PG; Perrone F; Mariani L; Gronchi A
    Clin Cancer Res; 2022 Sep; 28(18):4027-4032. PubMed ID: 35247923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis: The GRAFITI Trial.
    Schut AW; Timbergen MJM; van Broekhoven DLM; van Dalen T; van Houdt WJ; Bonenkamp JJ; Sleijfer S; Grunhagen DJ; Verhoef C
    Ann Surg; 2023 Apr; 277(4):689-696. PubMed ID: 35166264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.
    Nathenson MJ; Hu J; Ratan R; Somaiah N; Hsu R; DeMaria PJ; Catoe HW; Pang A; Subhawong TK; Amini B; Sweet K; Feister K; Malik K; Jagannathan J; Braschi-Amirfarzan M; Sheren J; Caldas Y; Moreno Tellez C; Rosenberg AE; Lazar AJ; Maki RG; Benedetto P; Cohen J; Trent JC; Ravi V; Patel S; Wilky BA
    Clin Cancer Res; 2022 Sep; 28(18):4092-4104. PubMed ID: 35180772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
    Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
    Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical application of next-generation sequencing for the management of desmoid tumors: A case report and literature review.
    Lee JM; Kim HG; Shin SY; Lee SH
    Medicine (Baltimore); 2021 Jan; 100(1):e24238. PubMed ID: 33429825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.